Treatment of Renal Vein Thrombosis in Venous Thromboembolism with Antiphospholipid Syndrome
Renal vein thrombosis occurring as part of venous thromboembolism (VTE) in a patient with antiphospholipid syndrome (APS) presents a specific management challenge, where the underlying autoimmune coagulopathy directly shapes anticoagulation strategy.
Clinical Scenario
This protocol addresses venous thromboembolism with antiphospholipid syndrome. Current evidence particularly emphasises the importance of antibody profile — patients with triple-positive APS (lupus anticoagulant, anticardiolipin, and anti-beta-2-glycoprotein 1 antibodies) represent a high-risk subset where anticoagulant choice matters. Recommendations favour vitamin K antagonists over direct oral anticoagulants (DOACs) for VTE treatment in this population.
Treatment Approach
When thrombosis occurs in the context of APS, management may involve adjustments to anticoagulation intensity or a change in anticoagulant class — and in some cases, the addition of an antiplatelet agent is considered.
The complete structured regimen — specific agents, sequencing, and decision criteria — is available in the full protocol.
References
Current recommendations favor the use of vitamin K antagonists over DOACs for VTE treatment in these patients, especially those with triple-positive antiphospholipid syndrome (presence of lupus anticoagulant, anticardiolipin, and anti-beta-2-glycoprotein 1 antibodies).
If patients experience a thrombotic event while on a therapeutic dose of warfarin, treatment options include increasing the target international normalized ratio, LMWH, and fondaparinux, or the addition of an antiplatelet agent.
DOI: 10.3949/ccjm.91a.22090
View source ↗